SCHEMBL4769035

SCHEMBL4769035

O=C(O)c1nc(N2CCCCS2(O)O)c2cccnc2c1O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CALCA P06881 7/20 0.60
COMT P21964 4/20 0.38
KDM4E B2RXH2 4/20 0.38
L3MBTL1 Q9Y468 3/20 0.38
KDM6B O15054 1/20 0.38
KDM6A O15550 1/20 0.38
TET3 O43151 1/20 0.38
KDM4A O75164 1/20 0.38
KDM4B O94953 1/20 0.38
KDM5C P41229 1/20 0.38
KDM4D Q6B0I6 1/20 0.38
TET2 Q6N021 1/20 0.38
ALKBH5 Q6P6C2 1/20 0.38
TET1 Q8NFU7 1/20 0.38
FTO Q9C0B1 1/20 0.38
EGLN1 Q9GZT9 1/20 0.38
KDM4C Q9H3R0 1/20 0.38
KDM2A Q9Y2K7 1/20 0.38
KDM3A Q9Y4C1 1/20 0.38
HTR6 P50406 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7258799 0.97 CALCA (0.56) CALCACOMTKDM4EL3MBTL1KDM6B
SCHEMBL4769028 0.89 CALCA (0.74) CALCACOMTKDM4EL3MBTL1KDM6B
SCHEMBL968122 0.87 CALCA (0.64) CALCACOMTKDM4EL3MBTL1EGLN1
SCHEMBL4067974 0.87 CALCA (0.56) CALCACOMTKDM4EL3MBTL1TP53
SCHEMBL7258795 0.85 CALCA (0.69) CALCACOMTKDM4EL3MBTL1KDM6B
SCHEMBL7262571 0.84 CALCA (0.53) CALCACOMTKDM4EL3MBTL1EGLN1
SCHEMBL4765018 0.83 CALCA (0.52) CALCACOMTKDM4EL3MBTL1KDM6B
SCHEMBL4764998 0.81 CALCA (0.54) CALCACOMTKDM4EL3MBTL1KDM6B
SCHEMBL4063925 0.81 CALCA (0.84) CALCATP53
SCHEMBL7257882 0.81 CALCA (0.68) CALCAEGLN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1496836-B1 N-(SUBSTITUTED BENZYL)-8-HYDROXY-1,6-NAPHTHYRIDINE-7- CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS MERCK & CO INC (US) 2008-09-24 EP disclosed
US-7323460-B2 N-(substituted benzyl)-8-hydroxy-1,6-naphthyridine-7-carboxamides useful as HIV integrase inhibitors MERCK & CO., INC. (US) 2008-01-29 US disclosed
EP-1496836-A4 N-(SUBSTITUTED BENZYL)-8-HYDROXY-1,6-NAPHTHYRIDINE-7- CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS MERCK & CO INC (US) 2006-03-22 EP disclosed
US-20050176955-A1 N-(substituted benzyl)-8-hydroxy-1,6-naphthyridine-7-carboxamides useful as hiv integrase inhibitors MERCK SHARP & DOHME CORP. 2005-08-11 US disclosed
US-20050165000-A1 Pharmaceutical compositions containing an hiv integrase inhibitor and a nonionic surfactant ROBERTSON SANDRA K (US) 2005-07-28 US disclosed
EP-1499391-A2 PHARMACEUTICAL COMPOSITIONS CONTAINING AN HIV INTEGRASE INHIBITOR AND A NONIONIC SURFACTANT Merck & Co., Inc. (US) 2005-01-26 EP disclosed
EP-1496836-A2 N-(SUBSTITUTED BENZYL)-8-HYDROXY-1,6-NAPHTHYRIDINE-7- CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS Merck & Co., Inc. (US) 2005-01-19 EP disclosed
US-20040220273-A1 Preparation of 2-aminomethyl-5-fluorobenzamides LEE JAEMOON (US) 2004-11-04 US disclosed
WO-2004080402-A2 POTASSIUM SALT OF AN HIV INTEGRASE INHIBITOR MERCK & CO. INC. (US) 2004-09-23 WO disclosed
WO-2003086319-A2 PHARMACEUTICAL COMPOSITIONS CONTAINING AN HIV INTEGRASE INHIBITOR AND A NONIONIC SURFACTANT MERCK & CO., INC. (US) 2003-10-23 WO disclosed
WO-2003077857-A2 N-(SUBSTITUTED BENZYL)-8-HYDROXY-1,6-NAPHTHYRIDINE-7- CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS MERCK & CO., INC. (US) 2003-09-25 WO disclosed
WO-2003077850-A2 N-(SUBSTITUTED BENZYL)-8-HYDROXY-1,6-NAPHTHYRIDINE-7- CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS MERCK & CO., INC. (US) 2003-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220273-A1 Preparation of 2-aminomethyl-5-fluorobenzamides CYP2B6, INTS6, HABP2 CALCA 4803/4885COMT 623/4885KDM4E 52/4885
US-20050176955-A1 N-(substituted benzyl)-8-hydroxy-1,6-naphthyridine-7-carboxamides useful as hiv integrase inhibitors CDK8, PNP, HINT1 CALCA 3871/4885COMT 1666/4885KDM4E 890/4885
US-20050165000-A1 Pharmaceutical compositions containing an hiv integrase inhibitor and a nonionic surfactant CDK7, INTS6, POLA1 CALCA 4164/4885COMT 1721/4885KDM4E 1850/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.